Category: Arthritis

Prime Therapeutics’ Studies Examine Rheumatoid Arthritis Therapies and Total Cost

ST. PAUL, Minn., Oct. 17, 2017 /PRNewswire/ — Two new studies by pharmacy benefit manager Prime Therapeutics LLC (Prime) show commercially insured members with rheumatoid arthritis (RA) had 3.5 times higher total cost of care than members without RA. But optimizing conventional disease… https://www.prnewswire.com/news-releases/prime-therapeutics-studies-examine-rheumatoid-arthritis-therapies-and-total-cost-300536842.html

Eli Lilly arthritis drug outperforms Humira and receives NICE backing

Eli Lilly’s rheumatoid arthritis (RA) drug Olumiant (baricitinib) has been deemed cost-effective by NICE and has been recommended to be used on the NHS for the treatment of severe active forms of the disease which has not responded to intensive therapy with conventional disease-modifying antirheumatic drugs (DMARDs), it has emerged.
read more http://www.pharmafile.com/news/514503/eli-lilly-arthritis-drug-outperforms-humira-and-receives-nice-backing

Pfizer’s rheumatoid arthritis drug shows treatment benefit in combination but not alone

Pfizer’s phase 3B/4 study evaluating its Xeljanz (tofacitinib citrate) drug, a treatment for moderate to severe rheumatoid arthritis (RA), met its primary endpoint in combination with methotrexate (MTX) against AbbVie’s adalimumab (Humira) but didn’t meet the primary endpoint on its own. http://clinicaltrials.pharmaceutical-business-review.com/news/pfizers-rheumatoid-arthritis-drug-shows-treatment-benefit-in-combination-but-not-alone-170217-5742191